These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 27959342)
1. Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. He Y; Peng S; Wang J; Chen H; Cong X; Chen A; Hu M; Qin M; Wu H; Gao S; Wang L; Wang X; Yi Z; Liu M Nat Commun; 2016 Dec; 7():13122. PubMed ID: 27959342 [TBL] [Abstract][Full Text] [Related]
2. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer. Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515 [No Abstract] [Full Text] [Related]
3. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer. Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482 [TBL] [Abstract][Full Text] [Related]
4. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer. Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514 [TBL] [Abstract][Full Text] [Related]
5. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685 [TBL] [Abstract][Full Text] [Related]
6. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer. Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K Mol Oncol; 2024 Aug; 18(8):1980-2000. PubMed ID: 38600681 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
8. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771 [TBL] [Abstract][Full Text] [Related]
9. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Cao B; Qi Y; Zhang G; Xu D; Zhan Y; Alvarez X; Guo Z; Fu X; Plymate SR; Sartor O; Zhang H; Dong Y Oncotarget; 2014 Mar; 5(6):1646-56. PubMed ID: 24722067 [TBL] [Abstract][Full Text] [Related]
10. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Wang R; Lin W; Lin C; Li L; Sun Y; Chang C Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475 [TBL] [Abstract][Full Text] [Related]
11. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Wu H; You L; Li Y; Zhao Z; Shi G; Chen Z; Wang Z; Li X; Du S; Ye W; Gao X; Duan J; Cheng Y; Tao W; Bian J; Zhou JR; Zhu Q; Yang Y Cancer Res; 2020 Jul; 80(13):2927-2939. PubMed ID: 32341037 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587 [TBL] [Abstract][Full Text] [Related]
13. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer. Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514 [TBL] [Abstract][Full Text] [Related]
14. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004 [TBL] [Abstract][Full Text] [Related]
15. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431 [TBL] [Abstract][Full Text] [Related]
17. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer. Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618 [TBL] [Abstract][Full Text] [Related]
18. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer. Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922 [TBL] [Abstract][Full Text] [Related]
19. Downregulation of Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112 [TBL] [Abstract][Full Text] [Related]
20. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Li Q; Deng Q; Chao HP; Liu X; Lu Y; Lin K; Liu B; Tang GW; Zhang D; Tracz A; Jeter C; Rycaj K; Calhoun-Davis T; Huang J; Rubin MA; Beltran H; Shen J; Chatta G; Puzanov I; Mohler JL; Wang J; Zhao R; Kirk J; Chen X; Tang DG Nat Commun; 2018 Sep; 9(1):3600. PubMed ID: 30190514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]